Please visit our MS learning channel on Youtube, providing you with hundreds of our education programs, filled with ms related topics that were video-recorded and archived here:

joomla ecommerce template -- Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 22, 2009

FDA confirms 3 new infections linked to Tysabri

FDA confirms 3 new infections linked to Tysabri

NEW YORK — The Food and Drug Administration says it confirmed three new cases of a potentially lethal brain inflammation linked to the multiple sclerosis drug Tysabri.

There have been 13 reported cases of progressive multifocal leukoencephalopathy, or PML, since mid-2006. The reports are the first confirmed new cases since June. While the disease is rare, the FDA says the risk appears to increase as patients remain on Tysabri.

Tysabri is marketed by Biogen Idec Inc. and Elan Corp. PLC, for multiple sclerosis and Crohn's disease. All the PML cases are linked to its use in multiple sclerosis.

The drug was approved in November 2004 and pulled from the market the next year due to PML reports. It was reintroduced in July 2006, and Biogen said it is used by 43,000 patients.


No comments: